TopoTarget

TopoTarget

File:TopoTarget logo.jpg

Logo of TopoTarget

TopoTarget was a biotechnology company focused on the development of cancer therapies. Founded in 2000, the company was based in Copenhagen, Denmark. TopoTarget specialized in the research and development of histone deacetylase inhibitors (HDAC inhibitors) and other targeted therapies for the treatment of cancer.

History

TopoTarget was established by a group of scientists and entrepreneurs with expertise in cancer research and drug development. The company aimed to develop innovative treatments that target specific mechanisms involved in cancer progression. In 2004, TopoTarget was listed on the Copenhagen Stock Exchange.

Research and Development

TopoTarget's research primarily focused on HDAC inhibitors, which are compounds that interfere with the function of histone deacetylases. These enzymes play a crucial role in the regulation of gene expression by modifying the chromatin structure. By inhibiting HDACs, TopoTarget aimed to reactivate tumor suppressor genes and induce apoptosis in cancer cells.

Hsp90, a protein targeted by some of TopoTarget's research

One of the company's lead compounds was belinostat, an HDAC inhibitor that showed promise in the treatment of various cancers, including peripheral T-cell lymphoma. Belinostat was developed in collaboration with other pharmaceutical companies and underwent several clinical trials.

Acquisition

In 2014, TopoTarget merged with BioAlliance Pharma, a French biotechnology company, to form Onxeo. This merger was aimed at creating a stronger entity with a broader portfolio of oncology products and a more extensive pipeline of drug candidates.

Related pages

• Histone deacetylase inhibitor
• Cancer treatment
• Onxeo

References

• Logo of TopoTarget
  Logo of TopoTarget
• 
  Image of Hsp90 protein